Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes

BMC Cancer

Shwn-Huey Shieh³  Janice C Probst²  Fung-Chang Sung⁴  Wen-Chen Tsai¹  Ya-Shin Li⁵  Chih-Yi Chen⁶ 

[1] Department of Health Services Administration, China Medical University, Taichung, 40402, Taiwan

[2] Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA

[3] Department of Nursing, China Medical University Hospital, Taichung, 40402, Taiwan

[4] Department of Medical Research, China Medical University Hospital, Taichung, 40402, Taiwan

[5] Department of Health Systems Management, Chung-Shan Medical University and Hospital, Taichung, 40201, Taiwan

[6] Cancer center, China Medical University Hospital, 2 Yu Der Road, Taichung, 40402, Taiwan

关键词: Tuberculosis;    Survival;    Diabetes;    Comorbidity;    Lung cancer;   

Others  :  1080433
DOI  :  10.1186/1471-2407-12-174

 received in 2011-10-07, accepted in 2012-05-11,  发布年份 2012

【 摘 要 】

Background

Comorbid conditions influence the survival of cancer patients. This study evaluated the influence of comorbidity on survival among lung cancer patients.

Methods

The authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan. Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with demographic status, comorbidity and cancer stage at diagnosis.

Results

On average, the survival time was slightly longer among women than among men (838 ± 689 vs. 749 ± 654 days, p = 0.050). Survival days increased with age (from 580 ± 526 [≤ 50 years] to 803 ± 693 [≥ 71 years] days, p = 0.020) and decreased with stage (from 1224 ± 656 [stage I] to 489 ± 536 [stage IV] days, p < 0.001). Younger patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days, p = 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend was observed in lung cancer patients with diabetes.

Conclusions

Lung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality. These patients deserve greater attention while undergoing cancer treatment.

【 授权许可】

   
2012 Shieh et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD: Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008, 26(1):54-59.
• [2]Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW: Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 2007, 43(15):2179-2193.
• [3]Lash TL, Thwin SS, Horton NJ, Guadagnoli E, Silliman RA: Multiple informants: a new method to assess breast cancer patients' comorbidity. Am J Epidemiol 2003, 157(3):249-257.
• [4]Ludbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, Martins H, Lim J: Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys 2003, 55(5):1321-1330.
• [5]Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW: Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 1999, 84(6):652-656.
• [6]Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994, 120(2):104-110.
• [7]Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW: Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998, 21(2):105-113.
• [8]Ogle KS, Swanson GM, Woods N, Azzouz F: Cancer and comorbidity: redefining chronic diseases. Cancer 2000, 88(3):653-663.
• [9]Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al.: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364(9):829-841.
• [10]van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW: Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999, 78(7):315-319.
• [11]Battafarano RJ, Piccirillo JF, Meyers BF, Hsu HS, Guthrie TJ, Cooper JD, Patterson GA: Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002, 123(2):280-287.
• [12]Budisin E: Comorbidity in Lung Cancer – Operated Patients, Impact on Survival and Prognosis. Evica Budisin, Washington, DC, USA; 2006.
• [13]Janssen-Heijnen ML, Smulders S, Lemmens VE, Smeenk FW, van Geffen HJ, Coebergh JW: Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004, 59(7):602-607.
• [14]Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: Impact of comorbidity on lung cancer survival. International journal of cancer Journal international du cancer 2003, 103(6):792-802.
• [15]Koyi H, Hillerdal G, Branden E: Patient's and doctors' delays in the diagnosis of chest tumors. Lung Cancer 2002, 35(1):53-57.
• [16]Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004, 125(1):27-37.
• [17]Hsu NY, Chen CY, Chung KP, Hsu CP, Hsia JY PYW: Pulmonary tuberculosis and lung cancer. Chin Med J 1996, 57(6):S140.
• [18]Piccirillo JF: Importance of comorbidity in head and neck cancer. Laryngoscope 2000, 110(4):593-602.
• [19]Bergman L, Dekker G, van Kerkhoff EH, Peterse HL, van Dongen JA, van Leeuwen FE: Influence of age and comorbidity on treatment choice and survival in elderly patients with breast cancer. Breast cancer research and treatment 1991, 18(3):189-198.
• [20]Firat S, Bousamra M, Gore E, Byhardt RW: Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 52(4):1047-1057.
• [21]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 1987, 40(5):373-383.
• [22]Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, Sullivan BO, Sobin LH, JW Y: AJCC Cancer Staging Manual (5th ed.). Lippincott-Raven Publishers, Philadelphia; 1997.
• [23]Bibb SC: The relationship between access and stage at diagnosis of breast cancer in African American and Caucasian women. Oncology nursing forum 2001, 28(4):711-719.
• [24]Caplan LS, Helzlsouer KJ, Shapiro S, Freedman LS, Coates RJ, Edwards BK: System delay in breast cancer in whites and blacks. Am J Epidemiol 1995, 142(8):804-812.
• [25]Dayal HH, Power RN, Chiu C: Race and socio-economic status in survival from breast cancer. Journal of chronic diseases 1982, 35(8):675-683.
• [26]Porta M, Gallen M, Malats N, Planas J: Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites. Journal of epidemiology and community health 1991, 45(3):225-230.
• [27]Moore KA, Mery CM, Jaklitsch MT, Estocin AP, Bueno R, Swanson SJ, Sugarbaker DJ, Lukanich JM: Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg 2003, 76(6):1789-1795.
• [28]Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. Journal of clinical epidemiology 2004, 57(6):597-609.
• [29]Bureau of Tobacco and Alcohol Monopoly: Annual Report of Tobacco, Alcohol Consumption Investigation in Taiwan Area. Taiwan Provincial Government, Taipei; 1993.
• [30]Ko YC, Lee CH, Chen MJ, Huang CC, Chang WY, Lin HJ, Wang HZ, Chang PY: Risk factors for primary lung cancer among non-smoking women in Taiwan. International journal of epidemiology 1997, 26(1):24-31.
• [31]Bureau of Health Promotion: Cancer Registry Annual Report, 2008. Department of Health, The Executive Yuan, Taipei, Taiwan; 2010.
• [32]Bureau of Health Promotion: Interactive Health Data Querying System. In. R.O.C. Department of Health, Taiwan; 2011.
• [33]Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, Sung FC, Chen CY: Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2011, 6(1):32-37.